To cite: Palm A, Theorell-

et al. Association between

cancer: a cross-sectional,

bmjopen-2022-064501

obstructive sleep apnoea and

population-based study of the

DISCOVERY cohort. BMJ Open

Prepublication history for

this paper is available online.

To view these files, please visit

the journal online (http://dx.doi.

org/10.1136/bmjopen-2022-

Received 09 May 2022

Accepted 20 January 2023

064501).

2023;13:e064501. doi:10.1136/

Haglöw J. Isakson J.

# **BMJ Open** Association between obstructive sleep apnoea and cancer: a cross-sectional, population-based study of the DISCOVERY cohort

Andreas Palm <sup>(D)</sup>, <sup>1,2</sup> J Theorell-Haglöw, <sup>1</sup> Johan Isakson <sup>(D)</sup>, <sup>3</sup> Mirjam Ljunggren, <sup>1</sup> Josefin Sundh <sup>(D)</sup>, <sup>4</sup> Magnus Per Ekström <sup>(D)</sup>, <sup>5</sup> Ludger Grote<sup>6</sup>

### ABSTRACT

**Objectives** Nocturnal hypoxia in obstructive sleep apnoea (OSA) is a potential risk factor for cancer. We aimed to investigate the association between OSA measures and cancer prevalence in a large national patient cohort. **Design** Cross-sectional study.

Settings 44 sleep centres in Sweden.

**Participants** 62 811 patients from the Swedish registry for positive airway pressure (PAP) treatment in OSA, linked to the national cancer registry and national socioeconomic data (the course of DIsease in patients reported to Swedish CPAP, Oxygen and VEntilator RegistrY cohort).

**Outcome measures** After propensity score matching for relevant confounders (anthropometric data, comorbidities, socioeconomic status, smoking prevalence), sleep apnoea severity, measured as Apnoea-Hypopnoea Index (AHI) or Oxygen Desaturation Index (ODI), were compared between those with and without cancer diagnosis up to 5 years prior to PAP initiation. Subgroup analysis for cancer subtype was performed.

**Results** OSA patients with cancer (n=2093) (29.8% females, age 65.3 (SD 10.1) years, body mass index 30 (IQR 27–34) kg/m<sup>2</sup>) had higher median AHI (n/hour) (32 (IQR 20-50) vs 30 (IQR 19-45), n/hour, p=0.002) and median ODI (n/hour) (28 (IQR 17-46) vs 26 (IQR 16-41), p<0.001) when compared with matched OSA patients without cancer. In subgroup analysis, ODI was significantly higher in OSA patients with lung cancer (N=57; 38 (21-61) vs 27 (16-43), p=0.012)), prostate cancer (N=617; 28 (17-46) vs 24, (16-39)p=0.005) and malignant melanoma (N=170; 32 (17-46) vs 25 (14-41),p=0.015). **Conclusions** OSA mediated intermittent hypoxia was independently associated with cancer prevalence in this large, national cohort, Future longitudinal studies are warranted to study the potential protective influence of OSA treatment on cancer incidence.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

Check for updates

For numbered affiliations see end of article.

Correspondence to Dr Andreas Palm;

Dr Andreas Palm; andreas.palm@medsci.uu.se

### INTRODUCTION

Patients with obstructive sleep apnoea (OSA) have recurring airway collapses during sleep with corresponding episodes of hypoxia. Animal models suggest an association between intermittent hypoxia and increased tumour growth, increased angiogenesis, changes in immune function and increases

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ The size of the cohort with a large number of patients with verified cancer diagnosis and concomitant obstructive sleep apnoea (OSA).
- ⇒ High external validity since the Swedevox registry reflects almost 90% of new continuous positive airway pressure treatment starts in Sweden initiated by 44 sleep centres across the country and the cancer registry has almost 100% coverage.
- ⇒ High internal validity since the Swedevox registry has been validated against medical record data entries and showed more than 95% correctness for age, body mass index and Apnoea-Hypopnoea Index values.
- ⇒ Important lifestyle risk factors for cancer including smoking, physical activity or food preferences have not been captured on an individual level in our study, but we included data on smoking prevalence in the different regions of Sweden to capture the potential influence of smoking on cancer prevalence.
- ⇒ Due to the cross-sectional design, our study cannot inform about the potential causality in the association between OSA and cancer.

in inflammation and oxidative stress.<sup>1</sup> Several studies investigated the potential causal relationship between OSA and cancer<sup>2-10</sup> and some but not all report an increased prevalence of cancer in the OSA population studied. A recent meta-analysis provided evidence for a 40%–50% increased risk ratio for cancer incidence in OSA patients.<sup>11</sup>

As OSA is associated with several other risk factors for cancer diseases, such as obesity, cardiometabolic disease and lifestyle factors, the independent influence of OSA-related hypoxia for an increased cancer risk remained unsolved. The validity of existing data may be in part hampered by the relatively low number of reported cancer cases, a potential reporting bias due to patient-reported cancer diagnosis without the validation of independent sources, as well as by a selection bias due to single-centre studies.

In Sweden, 85% of patients with OSA receiving continuous positive airway pressure (CPAP) are reported to the Swedevox registry<sup>12</sup> <sup>13</sup> and almost all patients diagnosed with cancer are reported to the mandatory governmental Cancer Registry.<sup>14</sup> The Swedish system with personal identity numbers<sup>15</sup> allows for cross-linkage of various registries, creating large databases with reliable data quality. Thereby, our current study aimed to overcome some of the limitations mentioned above by exploring the association between measures of OSA and cancer prevalence in a large, multicentric national cohort of OSA patients referred for PAP treatment using validated data from the national cancer registry for verified cancer diagnosis and subclassification.

### **METHODS**

### Study design and population

This was a national, population-based, cross-sectional study from the 'course of DIsease in patients reported to Swedish CPAP, Oxygen and VEntilator RegistrY' cohort. The study has been detailed elsewhere.<sup>13</sup> In this study, data on patients aged  $\geq 16$  years with OSA on CPAP therapy, correctly and prospectively reported to the Swedevox registry<sup>12</sup> between 1 July 2010 and 31 December 2017 were cross-linked with data from the mandatory National cancer registry<sup>16</sup> for information about cancer diagnosis, the Prescribed Drug Registry with information about all prescriptions of medications<sup>17</sup> and the National Patient Registry (NPR) covering data and diagnosis from all

inpatient and outpatient visits at governmental hospitals.<sup>18</sup> Socioeconomic data (marital status, education level) were covered from Statistics Sweden.<sup>19</sup> An overview of the study flow is presented in figure 1.

### **End-point variables and covariables**

The primary variable of interest was captured by the diagnose codes 'all-cause cancer' (International classification of Disease version 10 (ICD-10) code C00-99) up to 5 years prior initiation of CPAP therapy. Additional information was captured from organ specific cancer: ear, neck and throat cancer (ENT) (C1–14), colon (C18), lung (C34), malignant melanomas (C43), breast (C50), prostate (C61), urinary (C66–67) and malignant brain tumours (C71). Information on 'skin cancer' (C44) other than malign melanoma was excluded.

Information on sex, body mass index (BMI), Apnoea-Hypopnoea Index (AHI), Oxygen Desaturation Index (ODI), Epworth Sleepiness Scale score (ESS) and date of initiation of treatment were derived from the Swedevox registry.<sup>12 13</sup> Comorbid heart failure (ICD-10 codes I11, I42 and I50) and ischaemic heart disease (ICD-10 code I20-25) was derived from NPR.<sup>18</sup> Comorbid obstructive lung disease (OLD) was classified according to accepted practice by  $\geq 2$  collections of antiobstructive drugs (Anatomic Therapeutic Chemical classification system (ATC) code R03) ≤12 months prior to initiation of CPAP and comorbid diabetes was classified by  $\geq 1$  collection of antidiabetic drugs (A10)  $\leq 6$  months prior initiation of CPAP therapy was registered in the national Prescribed Drug Registry.<sup>17</sup> Information on educational level was obtained from Statistic Sweden and was categorised




Figure 1 Study flow chart. CPAP, continuous positive airway pressure; OSA, obstructive sleep apnoea

		Unmatched		Matched
	No cancer	All-cause cancer	No cancer	All-cause cancer
	N=59878	N=2933	N=2093	N=2093
Sex, females (%)	17647 (29.5%)	903 (30.8%)	661 (31.6%)	623 (29.8%)
Age, years	56.8 (12.5)	65.5 (10.2)	65.3 (10.2)	65.3 (10.1)
BMI, kg/m2	31 (28–35)	30 (27–34)	30 (27–34)	30 (27–34)
ESS, units	10.3 (5.0)	9.9 (4.9)	9.6 (4.9)	10.0 (4.9)
Ischaemic heart disease	5671 (9.5%)	425 (14.5%)	311 (14.9%)	309 (14.8%)
Heart failure	3263 (5.4%)	277 (9.4%)	180 (8.6%)	186 (8.9%)
Diabetes mellitus	8548 (14.3%)	526 (17.9%)	360 (17.2%)	366 (17.5%)
OLD	7610 (12.7%)	462 (15.8%)	325 (15.5%)	327 (15.6%)
Civil status				
Married	31926 (53.5%)	1771 (61.0%)	1300 (62.1%)	1280 (61.2%)
Unmarried	14675 (24.6%)	392 (13.5%)	289 (13.8%)	275 (13.1%)
Divorced	10561 (17.7%)	520 (17.9%)	340 (16.2%)	378 (18.1%)
Widower/widow	2529 (4.2%)	219 (7.5%)	164 (7.8%)	160 (7.6%)
Level of education				
Low (≤9 years)	10547 (21.7%)	605 (26.1%)	540 (25.8%)	546 (26.1%)
Medium (10–12 years)	25065 (51.5%)	1061 (45.8%)	977 (46.7%)	959 (45.8%)
High (≥13 years)	13060 (26.8%)	653 (28.2%)	576 (27.5%)	588 (28.1%)

Matched by anthropometric variables (sex, age, BMI), comorbidities at baseline (ischaemic heart disease, heart failure, diabetes mellitus and obstructive lung disease), socioeconomic factors (civil status and educational level), start year of CPAP treatment and county trichotomised by smoking prevalence. Data are presented as mean (SD) or median (IQR) for continuous measures, and n (%) for categorical measures. BMI, body mass index; CPAP, continuous positive airway pressure; ESS, Epworth Sleepiness Scale; OLD, obstructive lung disease.

as low ( $\leq$ 9 years), medium (10–12 years) or high ( $\geq$ 13 years), corresponding to compulsory school, secondary school and postsecondary school (college and university), respectively. The Swedevox registry does not contain information about individual smoking data. A marker for smoking exposure was generated from information on annual smoking prevalence between 2006 and 2018, in each county according to Statistics Sweden's Living Conditions Surveys (Undersökningen av levnadsförhållanden/ Survey on Income and Living Conditions, ULF/SILC).<sup>20</sup> Counties were trichotomised according to mean smoking rate (8.3%–12.0%, 12.1%–13.5% and 13.6%–14.8%).

### **Statistical analyses**

OSA severity was graded by the AHI and ODI both as continuous and categorical variables (AH! <5, 5 to <15 (mild OSA), 15 to <30 (moderate OSA) and  $\geq$ 30 (severe OSA)). Clinical cut-off values for ODI severity are not defined, and we, therefore, classified ODI into quartiles when used as a categorical variable. Association between sleep recording variables and all-cause cancer diagnosis  $\leq$ 5 years prior to the initiation of CPAP therapy was analysed. In detail, the relationship between prevalent all-cause cancer and organ-specific cancer and AHI and ODI were analysed using propensity score matched models.<sup>21</sup> For propensity score matching, independent covariables were used as anthropometrics (age, sex, BMI), presence of

comorbidities at baseline (ischaemic heart disease, heart failure, diabetes, OLD), socioeconomic data (civil status and educational level), start year of CPAP treatment and smoking prevalence (by county, trichotomised). These factors were chosen based on direct acyclic graphs using the browser-based environment DAGitty (www. dagitty. net).<sup>22</sup> In addition, we performed a parallel analysis applying logistic regression analysis in the entire baseline population to predict 'all-cause cancer diagnosis' independent of all mentioned covariates used for the propensity matching procedure.

Normally distributed continuous data were expressed as mean±SD, and skewed distributed data were expressed as median with IQR. Categorical data were presented as frequencies and percentages. Differences between groups were analysed using  $\chi^2$  test for categorical variables and Student's t-test for continuous variables. A p<0.05 was considered statistically significant. Statistical analyses were conducted using the software packages Stata, V.17.0 (StataCorp).

### Patient and public involvement

None.

Table 2OSA severity in propensity score matched patientswith OSA stratified by the presence of cancer diagnosis  $\leq 5$ years prior to initiation of CPAP treatment

	No cancer	All-cause	
	NO Cancer	cancer	
	N=2093	N=2093	P value
AHI, events/hour	30 (19–45)	32 (20–50)	0.002
AHI category, events/hour			0.19
AHI <5	15 (0.7%)	14 (0.7%)	
AHI 5–14.9	272 (13.0%)	247 (11.8%)	
AHI 15–29.9	718 (34.3%)	682 (32.6%)	
AHI ≥30	1088 (52.0%)	1150 (54.9%)	
ODI, events/hour	26 (16–41)	28 (17–46)	<0.001
ODI, quartiles, events/hour			0.002
ODI 0-15.9	501 (23.9%)	433 (20.7%)	
ODI 16-27.9	587 (28.0%)	576 (27.5%)	
ODI 28-44.9	569 (27.2%)	546 (26.1%)	
ODI ≥45	436 (20.8%)	538 (25.7%)	

Matched by anthropometric variables (sex, age, BMI),

comorbidities at baseline (ischaemic heart disease, heart failure, diabetes mellitus and obstructive lung disease), socioeconomic factors (civil status and educational level), start year of CPAP treatment and county trichotomised by smoking prevalence. Data are presented as median (IQR) for continuous measures, and n (%) for categorical measures.

AHI, Apnoea-Hypopnoea Index; BMI, body mass index; CPAP, continuous positive airway pressure; ODI, oxygen desaturation index; OSA, obstructive sleep apnoea.

### RESULTS Patient characteristics

Clinical data, in particular age and frequency of


comorbidities varied significantly between unmatched cases (N=2933) and controls (N=59878). The final propensity score matched study population consisted of 2096 patients with cancer (29.8% females, mean age 65.3 (SD 10.1) years, median BMI 30 (IQR 27–34) kg/m<sup>2</sup>) and 2096 matched OSA patients without cancer (table 1). Totally in the cohort, 91 patients had lung cancer, 46 ENT, 798 prostate cancer, 239 breast cancer, 191 colon cancer, 134 urinary cancer, 254 malignant melanoma and 16 malignant brain tumours ≤5 years prior to CPAP initiation.

After matching procedure, clinical characteristics did not differ between cases and controls except for the ESS score which was slightly elevated in cases compared with controls (ESS score 10.0 (SD 4.9) vs 9.6 (SD 4.9), p=0.02, respectively).

# Sleep apnoea severity in OSA patients with and without cancer

Cases with cancer disease had higher AHI (median 32 (IQR 20–50) vs 30 (19–45), n/hour, p=0.002) and ODI (28 (17–46) vs 26,<sup>16–41</sup> p<0.001) when compared with matched controls without cancer (table 2 and figure 2). Severe nocturnal intermittent hypoxia (ODI quartile IV (>45 n/hour)) was significantly more prevalent in cases (25.7%) compared with controls (20.8%), p=0.001 for ODI categories. Corresponding numbers for the highest AHI class ( $\geq$ 30 n/hour) were 54.9% in cases and 52.4% in controls but the differences in AHI categories did not reach statistical significance.

Subgroup analysis confirmed that ODI was significantly higher in OSA patients with lung cancer (N=57, median 38 (IQR 21–61) vs 27 (16–43), p=0.012)), prostate cancer (N=617, 28 (17–46) vs 24,<sup>16–39</sup> p=0.005) and malignant melanoma (N=170, 32 (17–46) vs 25,<sup>14–41</sup> p=0.015) when compared with corresponding OSA patients without



**Figure 2** Distribution of OSA patients with (red bars) and without (blue bars) cancer diagnosis in the four ODI quartiles (x-axis). Propensity score matched analysis in 2093 cases and 2093 controls, ODI distribution differs significantly between cases and controls, p<0.001. ODI, Oxygen Desaturation Index; OSA, obstructive sleep apnoea.

cancer (table 3). The remaining cancer subtypes did not differ in OSA severity measures.

In a parallel analysis including the entire cohort (N=62811), multivariable logistic regression analysis with cancer as the independent variable, and adjustment for the same variables as in the propensity score matching, we identified significant ORs for ODI and AHI (1.05 (1.03–1.07) and 1.04 (1.02–1.07) per 10 units, p<0.001, respectively) confirming the data obtained by propensity score matching.

### DISCUSSION Main findings

Our study identified several important findings. First, OSA is associated with cancer prevalence independent of a substantial number of important confounders. The added risk is small and predominantly seen in patients with severe intermittent hypoxia during sleep measured by ODI rather than in those with frequent respiratory events during sleep measured by AHI. Second, the association between intermittent hypoxia and cancer was identified in lung cancer, malignant melanoma and prostate cancer. Our study underlines the importance of further studies to investigate if preventing and treating sleep apnoea may have beneficial effects on cancer incidence and any outcomes of cancer treatment.

### Cancer prevalence in other cohort studies

Results from previous studies on OSA and cancer are conflicting. One early Spanish multicentre study (4910 patients) identified an increased cancer incidence in OSA patients with an overall OR of 1.45 (95% CI 1.1 to 1.9).<sup>2</sup> In a Canadian cohort study (n=10149) from a single sleep clinic at an academic hospital, 520 patients had a cancer diagnosis at baseline and 627 patients of the cancer-free patients at baseline were reported with incident cancer at follow-up (7.8 years).<sup>10</sup> No association between the severity of OSA and cancer was found for prevalent or incident cancer. In a twice as large European cross-sectional study (n=19556 of whom 388 self-reported cancer diagnosis at the time of sleep study), an association between AHI and ODI was found in women but not in men.<sup>8</sup> In a recent French cohort study (n=8748, 5.8year follow-up, 718 incident cancer cases), an association between nocturnal hypoxia, defined as the per cent of the night spent with saturation <90% and incident cancer was found while there were no associations between AHI or ODI and incident cancer after adjustment for confounders.<sup>9</sup> A recent meta-analysis of 12 studies, including 184915 patients with OSA (n=75367 and 3805 cancer cases) and patients without OSA (n=109548 and 2110 cancer cases) identified a dose-dependent increased risk of incident all-cause cancer with an OR of 1.14 (95% CI 1.04 to 1.25, p=0.006) for mild OSA, 1.36 (95% CI 1.32 to 1.92;p<0.001) for moderate OSA and 1.59 (95% CI 1.45 to 1.74; p<0.001) for severe OSA.<sup>11</sup> Unfortunately, this meta-analysis did not evaluate the association

between the amount of OSA-related hypoxic measures and cancer incidence. In this context, our cross-sectional data in one of the largest OSA patient populations so far is in line with previous findings. OSA appears to be associated with cancer, but effect sizes are generally small, and large cohorts are needed to detect any independent effect of OSA on cancer incidence. It cannot be excluded that other confounders, not vet considered in any of the published analyses, may further explain part of the effect sizes accounted for OSA. Notably, several studies show that OSA measures reflecting hypoxic burden appear to better predict the risk for cancer when compared with AHI as traditional OSA severity marker.<sup>89</sup> Due to the exact classification of cancer type through the Swedish national registry, we could perform subtype analysis on the influence of OSA-related cancers. We identified more severe OSA in lung cancer, malignant melanoma and in prostate cancer which is in line with previous study results.<sup>23–26</sup> In contrast, we did not identify an increased prevalence of OSA in patients with breast cancer.<sup>27 28</sup>

# Potential mechanisms between the association of OSA and cancer

Previous studies have explored potential mechanistic pathways for the association between OSA and cancer. Experimental studies mimicking OSA by using an intermittent hypoxia model show that intermittent hypoxia promotes incident tumour cell transition, tumour growth and metastasis. Several in vitro cell models identified intermittent hypoxia to promote tumour cell growth in different cell lines.<sup>29</sup> In vivo mouse models showed that melanoma metastasis was increased in animals exposed to intermittent hypoxia mimicking severe OSA.<sup>30</sup> Although these data suggest a possible OSA-related mechanistic pathway for cancer growth and aggressiveness, further studies are needed to explore if and how OSA promote the initial occurrence of cancer. In this context, obesity is an important confounder of the association between OSA and cancer. Obesity in the general population has nearly doubled in the last 20 years and by 2017, 17% of the Swedish adult population are obese, defined as BMI exceeding 30 kg/m<sup>2</sup>.<sup>31</sup> Presence of OSA is closely linked to obesity,<sup>32</sup> and in Sweden, the mean BMI when initiating CPAP therapy is  $32 \text{ kg/m}^{2.12}$  Several cancer forms, that is, breast, colon, kidney, pancreas and oesophageal cancer, are also associated with higher BMI.<sup>33</sup> As both agestandardised cancer incidence<sup>34</sup> and the prevalence of obesity are increasing<sup>31</sup> in parallel, we carefully controlled for both factors in our analysis.

Inflammation may be considered as a third potential pathway for the link between OSA and cancer. OSA increases systemic inflammation with increased levels of high-sensitivity C-reactive protein (hsCRP), Interleukin-6 (IL-6), and Tumour necrosis factor  $\alpha$  (TNF- $\alpha$ ).<sup>35 36</sup> Systemic inflammation has been linked to the risk of cancer/cancer development but also tumour growth.<sup>37</sup> In addition, a low degree of inflammation has been identified in adipocytes which may contribute to the

	Ψ
	Ş
	<u> </u>
	<u>S</u>
	ğ
	)pen: first
	₽
	ŝ,
	2
	₽
	÷
	\$
	ดี
	Ő.
	a
	õ
	<u> </u>
	0
	<u> </u>
	<u>~</u>
	β
	≌
	g.
	₫.
	O
	Š.
	Ψ.
	10.1136/bmjopen-2
	2022-064501 on 3 N
	3
	Ň
	5
	ത്
	4
	ğ
	5
	_
	9
	2
	ω
	$\leq$
	a
	aro
	÷
	N
	õ
	Ņ
	2023.
	ŏ
	š
	3
	5
	loa
	load
	loaded
	loaded 1
	loaded fro
	loaded fron
	loaded from
	published as 10.1136/bmjopen-2022-064501 on 3 March 2023. Downloaded from ht
-	loaded from http
-	loaded from http:/
1	tp://t
1	loaded from http://bmjope
1	tp://t
1	tp://bmjopen.bmj.com/ on April 1
1	tp://t
1	tp://bmjopen.bmj.com/ on April 1
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 1
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20
-	tp://bmjopen.bmj.com/ on April 17, 20

6

Continued

N=57   N=31     38 (25-56)   0.019   29 (18-46)   3     38 (25-56)   0.10   29 (18-46)   3     0   0   0   0   0     110   12 (21.1%)   15 (48.4%)   15 (48.4%)   15 (48.4%)     39 (68.4%)   39 (68.4%)   15 (48.4%)   15 (48.4%)   15 (48.4%)     39 (15.8%)   38 (21-61)   0.012   24 (15-46)   20 (10.5%)     38 (21-61)   0.012   24 (15-46)   20 (10.5%)   20 (1		No lung cancer	Lung cancer	P value	No ENT cancer	<b>ENT</b> cancer	P value	No prostate cancer	Prostate cancer	
28 (18-44)   38 (25-56)   0.019   29 (18-44)   30 (17-41)   0.30   28 (19-44)     0   0   0.10   0.10   29 (18-44)   0.03   28 (19-44)     1   0   0   0.10   1(3.2%)   7 (22.6%)   7 (0 (11.3%)     21 (56.8%)   12 (21.1%)   15 (48.4%)   8 (25.8%)   25 (40.7%)   25 (40.7%)     28 (49.1%)   38 (21-61)   0.012   24 (15-46)   21 (13.9%)   22 (14.5%)     28 (49.1%)   38 (21-61)   0.012   24 (15.9%)   11 (35.5%)   21 (14.0%)     13 (22.8%)   1 (12.5%)   8 (25.8%)   1 (135.5%)   1 (17.29.8%)     13 (22.8%)   1 (125.5%)   1 (125.5%)   1 (17.5%)   21 (14.0%)     13 (22.8%)   1 (125.5%)   1 (125.5%)   1 (12.9%)   1 (12.9%)     13 (22.8%)   1 (125.5%)   1 (125.5%)   1 (12.9%)   1 (11.9%)     13 (21.8%)   2 (16.1%)   1 (125.5%)   1 (12.9%)   1 (11.9%)     13 (22.8%)   1 (125.5%)   1 (125.5%)   1 (12.9%)   1 (12.9%) <th></th> <th>N=57</th> <th>N=57</th> <th></th> <th>N=31</th> <th>N=31</th> <th></th> <th>N=617</th> <th>N=617</th> <th></th>		N=57	N=57		N=31	N=31		N=617	N=617	
0   0.036   0 <td>AHI, events/hour</td> <td>28 (18–44)</td> <td>38 (25–56)</td> <td>0.019</td> <td>29 (18–46)</td> <td>30 (17–41)</td> <td>0.30</td> <td>28 (19–44)</td> <td>33 (20–50)</td> <td></td>	AHI, events/hour	28 (18–44)	38 (25–56)	0.019	29 (18–46)	30 (17–41)	0.30	28 (19–44)	33 (20–50)	
0   0	AHI category, events/hour			0.10			0.036			
8 (14.0%)   6 (10.5%)   1 (3.2%)   7 (2.5.%)   7 (0 (11.3%)     21 (36.8%)   12 (21.1%)   15 (48.4%)   8 (55.8%)   251 (40.7%)   251 (40.7%)     28 (43.1%)   39 (88.4%)   15 (48.4%)   15 (48.4%)   8 (51.6%)   29 (47.3%)     28 (43.1%)   39 (88.4%)   15 (48.4%)   15 (48.4%)   20 (13.5%)   29 (47.3%)     27 (16-43)   38 (21-61)   0.012   24 (15-49)   20 (13.5%)   14 (23.8%)     17 (23.8%)   17 (23.8%)   17 (23.8%)   11 (35.5%)   14 (12.9%)   13 (19.4%)     17 (23.8%)   9 (13.8%)   17 (23.8%)   10 (32.3%)   14 (12.9%)   13 (19.4%)     17 (23.8%)   17 (29.8%)   10 (32.3%)   11 (32.3%)   14 (12.9%)   13 (19.4%)     15 (21.1%)   26 (43.3%)   16 (31.4%)   10 (32.3%)   14 (12.9%)   13 (19.4%)     15 (21.9%)   28 (13.4%)   16 (32.5%)   11 (32.5%)   14 (12.9%)   13 (19.4%)     15 (26.3%)   21 (32.9%)   14 (23.9%)   14 (23.9%)   14 (12.9%)   13 (19.4%)     16	AHI<5	0	0		0	0		4 (0.6%)	2 (0.3%)	
21 (36.3%)   12 (21.1%)   15 (48.4%)   15 (48.4%)   15 (48.4%)   16 (40.7%)   22 (40.7%)     28 (43.1%)   38 (21-61)   0.012   24 (15-4%)   16 (41.6%)   292 (47.3%)     27 (16-43)   38 (21-61)   0.012   24 (15-4%)   16 (40.5%)   292 (47.3%)     27 (16-43)   38 (21-61)   0.012   24 (15-4%)   17 (23.3%)   210 (34.0%)     13 (22.8%)   17 (29.8%)   17 (29.8%)   11 (35.5%)   147 (23.3%)   147 (23.3%)     17 (29.9%)   17 (29.9%)   17 (29.9%)   10 (32.3%)   61 (34.0%)   139 (25.5%)     17 (29.9%)   17 (29.9%)   10 (32.3%)   61 (34.0%)   130 (32.5%)     16 (22.1%)   26 (43.9%)   10 (32.3%)   131 (19.6%)   131 (19.4%)     12 (21.1%)   26 (13.4%)   16 (12.5%)   131 (19.6%)   131 (19.4%)     12 (21.1%)   26 (43.9%)   13 (10.5%)   131 (19.4%)   131 (19.4%)     12 (21.1%)   26 (43.6%)   13 (10.6%)   131 (19.4%)   131 (19.4%)     12 (21.1%)   26 (13.4%)   26 (13.4%)	AHI 5-14.9	8 (14.0%)	6 (10.5%)		1 (3.2%)	7 (22.6%)		70 (11.3%)	66 (10.7%)	
28 (43.1 %)   39 (68.4 %)   15 (48.4 %)   16 (51.6 %)   22 (15-36)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   22 (17.3 %)   23 (17.3 %)	AHI 15-29.9	21 (36.8%)	12 (21.1%)		15 (48.4%)	8 (25.8%)		251 (40.7%)	208 (33.7%)	
27 (16-43)   38 (21-61)   0.012   24 (15-46)   23 (13-39)   0.22   24 (16-39)     0.034   0.034   0.034   0.21   24 (16-39)   0.21     13 (22.8%)   17 (29.8%)   17 (29.8%)   11 (35.5%)   147 (23.3%)     14 (29.8%)   17 (29.8%)   17 (29.8%)   10 (32.3%)   147 (29.8%)     15 (26.1%)   26 (13.4%)   10 (32.3%)   13 (13.6%)   13 (13.6%)     12 (21.1%)   25 (43.9%)   8 (25.8%)   4 (12.9%)   13 (19.6%)     No Breast cancer   Pvalue   No concancer   Pvalue   No uninay cancer     Ne 122   N = 162   N = 123   N = 123   N = 123   13 (19.47)     Ne 162   N = 162   N = 123   N = 123   0.41   31 (19.47)     Ne 162   N = 162   N = 123   N = 123   0.41   31 (19.47)     State sta	AHI>30	28 (49.1%)	39 (68.4%)		15 (48.4%)	16 (51.6%)		292 (47.3%)	341 (55.3%)	
0.034   0.21   0.21     13 (2.28%)   6 (10.5%)   8 (25.8%)   1 (35.5%)   1 (7 (23.8%))     17 (29.8%)   1 7 (29.8%)   1 (35.5%)   6 (19.4%)   210 (34.0%)     17 (29.8%)   9 (15.8%)   5 (16.1%)   1 (0 (22.3%)   1 (1 (2.9%))     12 (21.1%)   2 (12.9%)   1 (0 (22.3%)   1 (1 (2.9%))   1 (1 (3.9%))     No Breast cancer   P value   No con cancer   Colon cancer   P value   No uninary cancer     No Breast cancer   P value   No con cancer   N = 123   N = 123   N = 133     St (7 -46)   0.49   33 (21-53)   3 (21-43)   0.41   31 (19-47)     St (7 -46)   0.49   33 (21-53)   0.21   31 (19-47)   31 (19-47)     St (7 -46)   0.49   33 (21-53)   0.21-46)   0.41   31 (19-47)     St (7 -46)   2 (1 (2 %)   1 (1 (1 (1 %))   0.31   0.31   1 (1 (1 %))     St (1 -45)   2 (1 (1 %))   2 (1 (1 %))   0.31   0.31   0.31     13 (1 (1 6%)   1 (1 (1	ODI, events/hour	27 (16–43)	38 (21–61)	0.012	24 (15–46)	23 (13–39)	0.22	24 (16–39)	28 (17–46)	
13 (22.8%)   6 (10.5%)   8 (25.8%)   11 (35.5%)   147 (23.3%)     17 (29.8%)   17 (29.8%)   6 (19.4%)   210 (34.0%)     15 (26.3%)   9 (15.8%)   10 (32.3%)   6 (19.4%)   210 (34.0%)     15 (26.3%)   9 (15.8%)   5 (16.1%)   10 (32.3%)   139 (22.5%)     12 (21.1%)   25 (43.9%)   Noluciany   Nalue   No colon cancer   Poulue     No Breast cancer   Prastue   No colon cancer   Colon cancer   Poulue   No urinary cancer     N=162   N=162   N=162   N=123   N=123   N=103   N=103     N=162   N=162   N=162   N=123   N=123   No urinary cancer     N=162   N=162   N=162   N=123   N=123   N=123     28 (17-4%)   28 (18-46)   0.49   33 (21-53)   30 (21-48)   No urinary cancer     28 (17-4%)   28 (18-46)   0.49   33 (21-53)   30 (21-48)   0.41   141.1%     29 (17.9%)   21 (18-60)   21 (18-60)   23 (16.6%)   14 (11.9%)   13	ODI, quartiles, events/hour			0.034			0.21			
17 (29.8%)   17 (29.8%)   17 (29.8%)   10 (32.3%)   6 (19.4%)   20 (34.0%)     15 (26.3%)   9 (15.8%)   5 (16.1%)   10 (32.3%)   139 (22.5%)     12 (21.1%)   25 (43.9%)   8 (25.8%)   4 (12.9%)   121 (19.6%)     12 (21.1%)   25 (43.9%)   8 (25.8%)   4 (12.9%)   121 (19.6%)     No Breast cancer   Breast cancer   P value   No colon cancer   Colon cancer   P value     N=162   N=162   N=123   N=123   N=123   N=123     N=162   N=162   N=123   N=123   N=123   N=23     28 (17-46)   28 (18-46)   0.49   33 (21-53)   30 (21-48)   N=93     29 (17-9%)   28 (18-46)   0.41   31 (10.6%)   N=93     29 (17-9%)   28 (14-50)   13 (10.6%)   13 (14.0%)     51 (31.5%)   60 (37.0%)   35 (28.5%)   46 (37.4%)   26 (28.0%)     51 (31.5%)   28 (14-50)   28 (15-50)   26 (16.4%)   23 (10.6%)     29 (17.9%)   28 (14-50)   28 (15-60)   <	ODI 0-15.9	13 (22.8%)	6 (10.5%)		8 (25.8%)	11 (35.5%)		147 (23.8%)	129 (20.9%)	
15 (26.3%)   9 (15.8%)   5 (16.1%)   10 (32.3%)   139 (22.5%)     12 (21.1%)   25 (43.9%)   8 (25.8%)   4 (12.9%)   121 (19.6%)     No Breast cancer   Breast cancer   Value   No colon cancer   Colon cancer   Nuelso     N-162   N=162   N=162   N=123   N=123   N=93     N=162   N=162   N=162   N=162   N=163   N=93     28 (17-46)   28 (18-46)   0.49   33 (21-53)   30 (21-48)   N=93     28 (17-46)   28 (18-46)   0.49   33 (21-53)   30 (21-48)   N=93     28 (17-96)   28 (18-60)   10 (8.1%)   13 (10.6%)   14 (1.9%)   14 (1.9%)     29 (17.9%)   24 (14.3%)   10 (8.1%)   13 (10.6%)   13 (10.6%)   13 (14.0%)     51 (31.5%)   60 (37.0%)   35 (28.5%)   46 (37.4%)   26 (28.0%)   14 (1.9%)     51 (31.5%)   60 (37.0%)   21 (6%)   13 (10.6%)   13 (10.6%)   13 (11.6%)     51 (31.5%)   60 (37.0%)   26 (35.9%)   62 (37.9%) <t< td=""><td>ODI 16-27.9</td><td>17 (29.8%)</td><td>17 (29.8%)</td><td></td><td>10 (32.3%)</td><td>6 (19.4%)</td><td></td><td>210 (34.0%)</td><td>170 (27.6%)</td><td></td></t<>	ODI 16-27.9	17 (29.8%)	17 (29.8%)		10 (32.3%)	6 (19.4%)		210 (34.0%)	170 (27.6%)	
12 (21.1%)   25 (43.9%)   8 (25.8%)   4 (12.9%)   121 (19.6%)     No Breast cancer   Breast cancer   Value   No colon cancer   Colon cancer   P value   No urinary cancer     N=162   N=162   N=162   N=123   N=123   N=93     N=162   N=162   N=162   N=123   N=23   N=93     28 (17-46)   28 (18-46)   0.49   33 (21-53)   30 (21-48)   0.41   31 (19-47)     28 (17-46)   28 (18-46)   0.49   33 (21-53)   30 (21-48)   0.41   31 (19-47)     28 (17.9%)   28 (14-39)   27 (12.%)   10 (8.1%)   13 (10.6%)   13 (10.6%)   13 (19-47)     29 (17.9%)   26 (17.9%)   26 (14-39)   26 (14-39)   26 (28.0%)   26 (28.0%)     21 (31.5%)   60 (37.0%)   25 (28.5%)   62 (50.4%)   63 (57.0%)   26 (28.0%)     21 (31.5%)   76 (46.9%)   74 (60.2%)   26 (17-43)   0.47   26 (28.0%)     21 (31.5%)   76 (48.9%)   76 (60.2%)   26 (17-43)   0.47   28 (16-47)	ODI 28-44.9	15 (26.3%)	9 (15.8%)		5 (16.1%)	10 (32.3%)		139 (22.5%)	161 (26.1%)	
No Breast cancer   P value   No colon cancer   Colon cancer   P value   No uninary cancer     N=162   N=162   N=162   N=162   N=123   N=123   N=93     28 (17–46)   28 (18–46)   0.49   33 (21–53)   30 (21–48)   N=93     28 (17–46)   28 (18–46)   0.49   33 (21–53)   30 (21–48)   N=93     28 (17–9%)   2 (1.2%)   0.59   4 (3.3%)   2 (1.6%)   11 (1.1%)     29 (17.9%)   2 (17.9%)   2 (1.6%)   13 (10.6%)   13 (10.6%)     51 (31.5%)   60 (37.0%)   2 (1.6%)   13 (10.6%)   2 (2.6.0%)     51 (31.5%)   60 (37.0%)   35 (28.5%)   4 (37.4%)   2 (1.6.47)     29 (17.9%)   7 (46.9%)   7 (60.2%)   6 (17-43)   2 (16-47)     24 (14-39)   2 7 (17-49)   0.26   2 (1.6.4%)   2 (16-47)     29 (24.1%)   7 (460.2%)   6 (17-43)   0.47   2 (16-47)     24 (14.3%)   2 (14-39)   0.26   2 (1.6.4%)   2 (16-47)     29 (24.1%)   2 (17-43)	ODI >45	12 (21.1%)	25 (43.9%)		8 (25.8%)	4 (12.9%)		121 (19.6%)	157 (25.4%)	
N=162   N=162   N=162   N=162   N=163   N=103   N=93     28 (17-46)   28 (18-46)   0.49   33 (21-53)   30 (21-48)   0.41   31 (19-47)     28 (17-46)   28 (18-46)   0.49   33 (21-53)   30 (21-48)   0.41   31 (19-47)     4 (2.5%)   2 (1.2%)   4 (3.3%)   2 (1.6%)   1 (1.1%)   0.31     29 (17.9%)   24 (14.8%)   10 (8.1%)   13 (10.6%)   13 (10.6%)   13 (14.0%)     51 (31.5%)   60 (37.0%)   24 (14.8%)   13 (10.6%)   13 (10.6%)   13 (14.0%)     78 (48.1%)   76 (46.9%)   10 (8.1%)   13 (10.6%)   13 (14.0%)   26 (28.0%)     78 (14-39)   27 (17-49)   0.26   28 (18-50)   26 (17-43)   0.47   28 (16-47)     24 (14-39)   27 (17-49)   0.26   28 (18-50)   26 (17-43)   0.71   28 (57.0%)     24 (14-39)   27 (17-49)   0.26   28 (18-50)   26 (17-43)   0.71   28 (16-47)   28 (57.0%)     29 (21.0%)   38 (20.2%)   28 (18-50)		No Breast cancer	Breast cancer	P value	No colon cancer	Colon cancer	P value	No urinary cancer	Urinary cancer	
28 (17-46) 28 (18-46) 0.49 33 (21-53) 30 (21-48) 0.41 31 (19-47) $759$ 0.59 0.59 0.31 0.31 0.31 $4$ (2.5%) $2$ (12%) $2$ (12%) 10 (8.1%) 13 (10.6%) 11 (1.1%) $29$ (17.9%) $2$ (14.8%) $10$ (8.1%) 13 (10.6%) 13 (14.0%) $51$ (31.5%) $60$ (37.0%) $35$ (28.5%) $46$ (37.4%) $26$ (28.0%) $78$ (48.1%) $76$ (46.9%) $74$ (60.2%) $62$ (50.4%) $26$ (28.0%) $26$ (74.4%) $78$ (48.1%) $76$ (46.9%) $74$ (60.2%) $62$ (50.4%) $26$ (74.4%) $26$ (7		N=162	N=162		N=123	N=123		N=93	N=93	
0.59 0.59 0.31 0.31   2 (1.5%) 2 (1.2%) 4 (3.3%) 2 (1.6%) 1 (1.1%)   2 9 (17.9%) 2 (1.4.8%) 10 (8.1%) 13 (10.6%) 13 (14.0%)   9 51 (31.5%) 60 (37.0%) 35 (28.5%) 46 (37.4%) 26 (28.0%)   9 51 (31.5%) 60 (37.0%) 35 (28.5%) 46 (37.4%) 26 (28.0%)   9 51 (31.5%) 60 (37.0%) 35 (28.5%) 46 (37.4%) 26 (28.0%)   10 24 (14-39) 27 (17-49) 0.26 28 (18-50) 26 (17-43) 0.47 28 (16-47)   10 24 (14-39) 27 (17-49) 0.26 28 (18-50) 26 (17-43) 0.47 28 (16-47) 28 (16-47)   10 31 (30.2%) 32 (30.5%) 26 (21.1%) 0.47 28 (16-47) 20 (21.5%) 2	AHI, events/hour	28 (17–46)	28 (18–46)	0.49	33 (21–53)	30 (21–48)	0.41	31 (19–47)	35 (24–52)	
4(2.5%) $2(1.2%)$ $2(1.2%)$ $4(3.3%)$ $2(1.6%)$ $1(1.1%)$ $29(17.9%)$ $24(14.8%)$ $10(8.1%)$ $13(10.6%)$ $13(14.0%)$ $51(31.5%)$ $60(37.0%)$ $35(28.5%)$ $46(37.4%)$ $26(28.0%)$ $51(31.5%)$ $60(37.0%)$ $35(28.5%)$ $46(37.4%)$ $26(28.0%)$ $78(48.1%)$ $76(46.9%)$ $74(60.2%)$ $62(50.4%)$ $26(20%)$ $24(14-39)$ $27(17-49)$ $0.26$ $28(18-50)$ $26(17-43)$ $0.47$ $24(14-39)$ $27(17-49)$ $0.26$ $28(18-50)$ $26(17-43)$ $0.47$ $24(14-39)$ $27(17-49)$ $0.26$ $28(18-50)$ $26(17-43)$ $28(16-47)$ $39(24.1%)$ $38(23.5%)$ $24(19.5%)$ $26(21.1%)$ $27(25%)$ $39(24.1%)$ $34(21.0%)$ $34(27.6%)$ $36(29.3%)$ $26(21.1%)$ $26(28.0%)$ $39(24.1%)$ $34(21.0%)$ $34(27.6%)$ $36(29.3%)$ $26(29%)$ $26(28.0%)$ $39(24.1%)$ $49(30.2%)$ $34(27.6%)$ $36(29.3%)$ $22(28.0%)$ $26(28.0%)$ $34(21.0%)$ $40(24.7%)$ $28(23.6%)$ $29(23.6%)$ $22(28.0%)$ $100$ malignantMalignantNo malignantNullemantNullemant $100$ malignant $100$ malignant $100$ malignant $100$ malignant $100$ malignant	AHI category, events/hour			0.59			0.31			
29 (17.9%) $24 (14.8%)$ $10 (8.1%)$ $13 (10.6%)$ $13 (14.0%)$ $51 (31.5%)$ $60 (37.0%)$ $35 (28.5%)$ $46 (37.4%)$ $26 (28.0%)$ $78 (48.1%)$ $76 (46.9%)$ $55 (28.0%)$ $26 (28.0%)$ $26 (28.0%)$ $78 (48.1%)$ $76 (46.9%)$ $0.26$ $28 (18-50)$ $26 (17-43)$ $26 (28.0%)$ $24 (14-39)$ $27 (17-49)$ $0.26$ $28 (18-50)$ $26 (17-43)$ $28 (16-47)$ $24 (14-39)$ $27 (17-49)$ $0.26$ $28 (18-50)$ $26 (17-43)$ $28 (16-47)$ $24 (14-39)$ $37 (17-49)$ $0.26$ $28 (18-50)$ $26 (17-43)$ $28 (16-47)$ $38 (23.5%)$ $38 (23.5%)$ $28 (18-50)$ $26 (17-43)$ $0.47$ $28 (16-47)$ $49 (30.2%)$ $38 (23.5%)$ $24 (19.5%)$ $26 (21.1%)$ $20 (21.5%)$ $39 (24.1%)$ $34 (21.0%)$ $34 (27.6%)$ $36 (29.3%)$ $26 (28.0%)$ $34 (21.0%)$ $31 (30.1%)$ $29 (23.6%)$ $22 (23.7%)$ $140 (24.7%)$ $41 (25.3%)$ $21 (30.1%)$ $29 (23.6%)$ $140 (24.7%)$ $14 (25.3%)$ $29 (23.6%)$ $22 (23.7%)$ $140 (24.7%)$ $14 (25.3%)$ $28 (20.3%)$ $29 (23.6%)$ $140 (24.7%)$ $12 (10%)$ $29 (23.6%)$ $22 (23.7%)$ $140 (24.7%)$ $14 (25.3%)$ $28 (20.9%)$ $22 (23.7%)$ $140 (24.7%)$ $14 (25.3%)$ $29 (20.9%)$ $29 (23.6%)$ $140 (24.7%)$ $14 (26.3%)$ $14 (26.3%)$ $14 (26.3%)$ $140 (24.7%)$ $14 (26.3%)$ $14 (26.3%)$ <	AHI <5	4 (2.5%)	2 (1.2%)		4 (3.3%)	2 (1.6%)		1 (1.1%)	1 (1.1%)	
51 (31.5%)60 (37.0%)35 (28.5%)46 (37.4%)26 (28.0%)78 (48.1%)76 (46.9%)74 (60.2%)62 (50.4%)53 (57.0%)24 (14-39)27 (17-49)0.2628 (18-50)26 (17-43)0.4728 (16-47)24 (14-39)27 (17-49)0.2628 (18-50)26 (17-43)0.4728 (16-47)24 (19.5%)0.302.02.02.02.02.049 (30.2%)38 (23.5%)24 (19.5%)26 (21.1%)20 (21.5%)39 (24.1%)38 (23.5%)24 (19.5%)36 (23.3%)26 (28.0%)40 (24.7%)34 (21.0%)28 (22.8%)32 (26.0%)22 (23.7%)No malignantMalignattNo malignant brainMalignant brainMalignant brainMolonantMalignant brainMalignant brainMalignant brainMalignant brain	AHI 5-14.9	29 (17.9%)	24 (14.8%)		10 (8.1%)	13 (10.6%)		13 (14.0%)	6 (6.5%)	
78 (48.1%)76 (46.9%)74 (60.2%)62 (50.4%)53 (57.0%) $24 (14-39)$ $27 (17-49)$ $0.26$ $28 (18-50)$ $26 (17-43)$ $0.47$ $28 (16-47)$ $24 (14-39)$ $27 (17-49)$ $0.26$ $28 (18-50)$ $26 (17-43)$ $0.47$ $28 (16-47)$ $49 (30.2\%)$ $38 (23.5\%)$ $2.4 (19.5\%)$ $26 (21.1\%)$ $2.7 (5\%)$ $39 (24.1\%)$ $38 (23.5\%)$ $34 (27.6\%)$ $36 (29.3\%)$ $20 (21.5\%)$ $40 (24.7\%)$ $34 (21.0\%)$ $28 (22.8\%)$ $32 (26.0\%)$ $22 (23.7\%)$ $34 (21.0\%)$ $41 (25.3\%)$ $28 (22.8\%)$ $22 (23.7\%)$ $22 (23.7\%)$ No malignantMalignattP valueNo malignantP valueModernantMalignattP valueNo malignantP value	AHI 15-29.9	51 (31.5%)	60 (37.0%)		35 (28.5%)	46 (37.4%)		26 (28.0%)	30 (32.3%)	
24 (14-39) 27 (17-49) 0.26 28 (18-50) 26 (17-43) 0.47 28 (16-47)   0.30 0.30 0.30 0.31 0.71 28 (16-47) 28   49 (30.2%) 38 (23.5%) 24 (19.5%) 26 (21.1%) 20 (21.5%) 20   39 (24.1%) 38 (23.5%) 24 (19.5%) 26 (21.1%) 20 (21.5%) 26   39 (24.1%) 34 (21.0%) 28 (22.8%) 32 (26.0%) 26 (28.0%) 26   31 (21.0%) 34 (21.0%) 28 (22.8%) 32 (26.0%) 22 (23.7%) 24   No malignant Malignat P value No malignant brain Malignant brain Palue Nalignant brain Palue	AHI >30	78 (48.1%)	76 (46.9%)		74 (60.2%)	62 (50.4%)		53 (57.0%)	56 (60.2%)	
0.30 0.30   49 (30.2%) 38 (23.5%) 24 (19.5%) 26 (21.1%) 20 (21.5%)   9 39 (24.1%) 49 (30.2%) 34 (27.6%) 36 (29.3%) 26 (28.0%)   9 40 (24.7%) 34 (21.0%) 28 (22.8%) 32 (26.0%) 22 (23.7%)   10 41 (25.3%) 37 (30.1%) 29 (23.6%) 25 (26.9%) 2   10 Malignant Malignant P value No malignant P value No malignant P value	ODI, events/hour	24 (14–39)	27 (17–49)	0.26	28 (18–50)	26 (17–43)	0.47	28 (16–47)	32 (21–50)	
49 (30.2%) 38 (23.5%) 24 (19.5%) 26 (21.1%) 20 (21.5%)   39 (24.1%) 49 (30.2%) 34 (27.6%) 36 (29.3%) 26 (28.0%)   40 (24.7%) 34 (21.0%) 28 (22.8%) 32 (26.0%) 26 (28.0%)   34 (21.0%) 34 (21.0%) 28 (22.8%) 32 (26.0%) 22 (23.7%)   34 (21.0%) 41 (25.3%) 23 (30.1%) 29 (23.6%) 25 (26.9%)   No malignant Malignant P value No malignant P value	ODI, quartiles, events/hour			0.30			0.71			
39 (24.1%) 49 (30.2%) 34 (27.6%) 36 (29.3%) 26 (28.0%)   40 (24.7%) 34 (21.0%) 28 (22.8%) 32 (26.0%) 22 (23.7%)   34 (21.0%) 41 (25.3%) 28 (22.8%) 32 (26.0%) 22 (23.7%)   No malignant Malignat P value No malignant P value   Molanda Malignation P value No malignant P value	ODI 0-15.9	49 (30.2%)	38 (23.5%)		24 (19.5%)	26 (21.1%)		20 (21.5%)	14 (15.1%)	
40 (24.7%) 34 (21.0%) 28 (22.8%) 32 (26.0%) 22 (23.7%)   34 (21.0%) 41 (25.3%) 37 (30.1%) 29 (23.6%) 25 (26.9%)   No malignant Malignant P value No malignant P value   Modernona Modernona 41 (25.3%) 29 (23.6%) 25 (26.9%)	ODI 16-27.9	39 (24.1%)	49 (30.2%)		34 (27.6%)	36 (29.3%)		26 (28.0%)	25 (26.9%)	
34 (21.0%) 41 (25.3%) 37 (30.1%) 29 (23.6%) 25 (26.9%) No malignant Malignat P value No malignat brain Malignant P value	ODI 28-44.9	40 (24.7%)	34 (21.0%)		28 (22.8%)	32 (26.0%)		22 (23.7%)	25 (26.9%)	
Malignat P value No malignat brain Malignant	ODI >45	34 (21.0%)	41 (25.3%)		37 (30.1%)	29 (23.6%)		25 (26.9%)	29 (31.2%)	
		No malignant melanoma	Malignat	P value	No malignat brain		P value			

P value

0.15 0.40 0.11 0.67

P value

0.006 0.035 0.005 0.009 6

Table 3 Continued									
	No lung cancer	Lung cancer	P value	No ENT cancer	<b>ENT</b> cancer	P value	No prostate cancer Prostate cancer	Prostate cancer	P value
	N=57	N=57		N=31	N=31		N=617	N=617	
	N=170	N=170		N=8	N=8				
AHI, events/hour	28 (17–45)	35 (23–52)	0.003	31 (12–40)	40 (16–54)	0.25			
AHI category, events/hour			0.072			0.86			
AHI <5	2 (1.2%)	1 (0.6%)		0	0				
AHI 5-14.9	25 (14.7%)	15 (8.8%)		2 (25.0%)	2 (25.0%)				
AHI 15-29.9	65 (38.2%)	53 (31.2%)		1 (12.5%)	1 (12.5%)				
AHI >30	78 (45.9%)	101 (59.4%)		5 (62.5%)	5 (62.5%)				
ODI, events/hour	25 (14–41)	32 (17–46)	0.015	29 (13–34)	36 (15–56)	0.19			
ODI, quartiles, events/hour			0.13			0.28			
ODI 0-15.9	48 (28.2%)	32 (18.8%)		3 (37.5%)	2 (25.0%)				
ODI 16-27.9	47 (27.6%)	45 (26.5%)		1 (12.5%)	1 (12.5%)				
ODI 28-44.9	44 (25.9%)	50 (29.4%)		4 (50.0%)	2 (25.0%)				
ODI >45	31 (18.2%)	43 (25.3%)		0 (0.0%)	3 (37.5%)				
Matched by anthropometric variables (sex, age, BMI), comorbidities (civil status and educational level), start year of CPAP treatment and Data are presented as median (IQR) for continuous measures, and n AHI, Apnoea-Hypopnoea Index; BMI, body mass index; CPAP, contir	Matched by anthropometric variables (sex, age, BMI), comorbidities (civil status and educational level), start year of CPAP treatment and Data are presented as median (IQR) for continuous measures, and n AHI, Apnoea-Hypopnoea Index; BMI, body mass index; CPAP, contir	ge, BMI), comorbidi of CPAP treatment a nuous measures, an tass index; CPAP, oc	ties at baselir and county tri d n (%) for ce ontinuous pos	at baseline (ischaemic heart dis county trichotomised by smokii (%) for categorical measures. uous positive airway pressure;	sease, heart failure ng prevalence. AH ENT, ear, nose an	e, diabetes me II and ODI are Id throat; ODI,	Matched by anthropometric variables (sex, age, BMI), comorbidities at baseline (ischaemic heart disease, heart failure, diabetes mellitus and obstructive lung disease), socioeconomic factors (civil status and educational level), start year of CPAP treatment and county trichotomised by smoking prevalence. AHI and ODI are expressed as both continuous and categorised variables. Data are presented as median (IQR) for continuous measures, and n (%) for categorical measures. AHI, Apnoea-Hypopnoea Index; BMI, body mass index; CPAP, continuous positive airway pressure; ENT, ear, nose and throat; ODI, Oxygen Desaturation Index; OSA, obstructive sleep	disease), socioeconom ous and categorised v k; OSA, obstructive sle	lic factors ariables. ep

apnoea.

overall increased inflammation in obesity. Further studies linking markers of inflammation to cancer incidence in OSA populations are of particular interest.

Our study has several strengths. First, the study has a high validity as we included a large number of patients with a verified cancer diagnosis and concomitant OSA. The National cancer registry has the highest quality due to regularly performed validation studies by the National Social Welfare Board. The sleep apnoea-related data within the Swedevox registry has recently been validated against the medical record data entries and showed more than 95% correctness for age, BMI and AHI values.<sup>38</sup> Second, our study cohort is representative for studying the association between OSA and cancer prevalence. The Swedevox registry reflects almost 90% of new CPAP treatment starts in Sweden initiated by 44 sleep centres across the country.<sup>12</sup> The national cancer registry has nearly 100% coverage.<sup>16</sup> Socioeconomic data are based on information from the National Tax Agency. No patient was lost due to missing data in the national registries. Third, we used a strong analysis methodology with sufficient power due to a large number of cases. The propensity score matching of cases and controls adjusting for many important confounders can be viewed as close to a randomised study setting. A parallel multivariable Coxregression analysis confirmed the results of the propensity score matched analysis.

Nonetheless study limitations need also to be addressed. First, sleep apnoea within the Swedevox registry is almost exclusively classified by polygraphy and not by polysomnography. However, device methodology is very homogeneous in Sweden and national guidelines for the analysis of polygraphic recordings are published.<sup>39</sup> Polygraphic recording may underestimate the actual AHI classification but to a lesser extent, the ODI count. This may, in part explain why ODI is a stronger predictor of cancer prevalence than AHI. Second, we do not have other measures of nocturnal hypoxia other than ODI, for example, the time spent in saturation below 90% or hypoxic burden analysis of the saturation curve, recently described as a significant predictor of cancer in OSA patients.<sup>28940</sup> Third, important lifestyle risk factors for cancer, including smoking, physical activity or food preferences, have not been captured on an individual level in our study. However, we have a strong classification of socioeconomic factors. We also included data on smoking prevalence in the different regions of Sweden to capture the potential influence of smoking on cancer prevalence. Research into the impact of socioeconomic factors on cancer incidence typically find a larger prevalence of solid tumours in groups with less fortunate social standing with breast cancer being the sole outlier. The single most important variable in cancer incidence is tobacco smoking where large differences are seen between socioeconomic groups.<sup>41</sup> In case of lacking information on individual patient data for such risk factors, the use of socioeconomic stratification represents the best available method to adjust for this. Fourth, our study included only PAP-treated OSA patients reflecting

the upper range of OSA severity and not the entire OSA spectrum. This patient selection may have limited our possibility to fully assess the dose response relationship between OSA severity and cancer prevalence. However, the OSA patient group with severe intermittent hypoxia demonstrated the strongest risk increase for cancer prevalence. Finally, due to the cross-sectional study design, our study cannot speculate about the causality in the association between OSA and cancer.

### **Clinical implications and research agenda**

Our study provides further cross-sectional evidence to the important clinical question of the association between OSA and cancer in OSA patients. Even if we did not analyse longitudinal data on the incidence of cancer, we see a significant yet limited effect size for OSA on the risk for prevalent cancer. More importantly, future analysis needs to focus on the effect of OSA treatment with PAP on cancer incidence and survival.

### CONCLUSION

OSA mediated intermittent hypoxia is an independent risk factor for cancer in this large, national OSA patient cohort. Future longitudinal studies are warranted to study the potential influence of OSA treatment on cancer incidence in patients with OSA.

#### **Author affiliations**

<sup>1</sup>Department of Medical Sciences, Lung, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden

<sup>2</sup>Centre for Research and Development, Region of Gävleborg Gävle Hospital, Gävle, Sweden

<sup>3</sup>Centre for Research and Development, Region of Gävleborg, Gävle Hospital, Gävle, Sweden

<sup>4</sup>Department of Respiratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

<sup>5</sup>Department of Clinical Sciences, Respiratory Medicine and Allergology, Lund University, Lund, Sweden, Lund, Sweden

<sup>6</sup>Sahlgrenska Academy, Gothenburg University, Centre for Sleep and Wake Disorders, Goteborg, Sweden

**Contributors** AP, JT-H, JI, ML, JS, MPE and LG contributed to the conception and design of the study. AP performed statistical analyses, and all authors verified the underlying data. AP and LG wrote the first draft. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. All authors participated in data interpretation, drafting of the manuscript and final approval for submission. AP is responsible for the overall content as a guarantor.

**Funding** AP was supported by grants from Gävle Cancer Foundation (grant number N/A), the Swedish Society for Sleep Research and Sleep Medicine (grant number N/A), Centre for Research and Development, Uppsala University/Region Gävleborg (grant number N/A), Bror Hjerpstedt's Foundation (grant number N/A) and Uppsala Heart and Lung Foundation (grant number N/A) and Regional Research Council in Mid Sweden (RFR-931234). JT-H was supported by a grant from Swedish Heart and Lung Foundation (20190607, 20190611). MPE was supported by unrestricted grants from the Swedish Research Council (Dnr 2019-02081). LG was supported by the Swedish Heart and Lung Foundation (20180567, 20210529).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

**Data availability statement** Data are available on reasonable request. The steering committee of the Swedevox quality registry will consider reasonable requests for the sharing of deidentified patient-level data. Requests should be made to the corresponding author.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/ licenses/by/4.0/.

#### **ORCID** iDs

Andreas Palm http://orcid.org/0000-0002-0590-0417 Johan Isakson http://orcid.org/0000-0001-5787-0072 Josefin Sundh http://orcid.org/0000-0003-1926-8464 Magnus Per Ekström http://orcid.org/0000-0002-7227-5113

### REFERENCES

- Almendros I, Montserrat JM, Torres M, et al. Obesity and intermittent hypoxia increase tumor growth in a mouse model of sleep apnea. Sleep Med 2012;13:1254–60.
- 2 Campos-Rodriguez F, Martinez-Garcia MA, Martinez M, et al. Association between obstructive sleep apnea and cancer incidence in a large multicenter spanish cohort. Am J Respir Crit Care Med 2013;187:99–105.
- 3 Christensen AS, Clark A, Salo P, et al. Symptoms of sleep disordered breathing and risk of cancer: a prospective cohort study. Sleep 2013;36:1429–35.
- 4 Nieto FJ, Peppard PE, Young T, *et al*. Sleep-disordered breathing and cancer mortality: results from the wisconsin sleep cohort study. *Am J Respir Crit Care Med* 2012;186:190–4.
- 5 Chang W-P, Liu M-E, Chang W-C, *et al*. Sleep apnea and the subsequent risk of breast cancer in women: a nationwide population-based cohort study. *Sleep Med* 2014;15:1016–20.
- 6 Chen J-C, Hwang J-H. Sleep apnea increased incidence of primary central nervous system cancers: a nationwide cohort study. *Sleep Med* 2014;15:749–54.
- 7 Gozal D, Farré R, Nieto FJ. Putative links between sleep apnea and cancer: from hypotheses to evolving evidence. *Chest* 2015;148:1140–7.
- 8 Pataka A, Bonsignore MR, Ryan S, *et al*. Cancer prevalence is increased in females with sleep apnoea: data from the ESADA study. *Eur Respir J* 2019;53:1900091.
- 9 Justeau G, Gervès-Pinquié C, Le Vaillant M, *et al.* Association between nocturnal hypoxemia and cancer incidence in patients investigated for OSA: data from a large multicenter french cohort. *Chest* 2020;158:2610–20.
- 10 Kendzerska T, Leung RS, Hawker G, et al. Obstructive sleep apnea and the prevalence and incidence of cancer. CMAJ 2014;186:985–92.
- 11 Cheng H, Li D. Investigation into the association between obstructive sleep apnea and incidence of all-type cancers: a systematic review and meta-analysis. *Sleep Med* 2021;88:274–81.
- 12 The Swedevox registry. Annual report. 2020. Available: https://www. ucr.uu.se/swedevox/rapporter/arsrapporter/arsrapport-2020
- 13 Palm A, Ågren K, Grote L, et al. Course of disease in patients reported to the swedish CPAP oxygen and ventilator registry (DISCOVERY) with population-based controls. *BMJ Open* 2020;10:e040396.
- 14 Barlow L, Westergren K, Holmberg L, et al. The completeness of the swedish cancer register: a sample survey for year 1998. Acta Oncol 2009;48:27–33.
- 15 Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009;24:659–67.
- 16 Pukkala E, Engholm G, Højsgaard Schmidt LK, et al. Nordic cancer registries - an overview of their procedures and data comparability. *Acta Oncol* 2018;57:440–55.
- 17 Wettermark B, Hammar N, Fored CM, et al. The new swedish prescribed drug register--opportunities for pharmacoepidemiological research and experience from the first six months. *Pharmacoepidemiol Drug Saf* 2007;16:726–35.

- 18 Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the swedish national inpatient register. BMC Public Health 2011;11:450.
- 19 Ludvigsson JF, Svedberg P, Olén O, *et al*. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. *Eur J Epidemiol* 2019;34:423–37.
- 20 Living conditions surveys (ULF/SILC). 2019. Available: http://www.scb.se/le0101-en
- 21 Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. *Multivariate Behav Res* 2011;46:399–424.
- 22 Lederer DJ, Bell SC, Branson RD, *et al.* Control of confounding and reporting of results in causal inference studies. guidance for authors from editors of respiratory, sleep, and critical care journals. *Ann Am Thorac Soc* 2019;16:22–8.
- 23 Cheong AJY, Tan BKJ, Teo YH, et al. Obstructive sleep apnea and lung cancer: a systematic review and meta-analysis. Ann Am Thorac Soc 2022;19:469–75.
- 24 Martinez-Garcia MA, Campos-Rodriguez F, Nagore E, et al. Sleepdisordered breathing is independently associated with increased aggressiveness of cutaneous melanoma: a multicenter observational study in 443 patients. Chest 2018;154:1348–58.
- 25 Chung WS, Lin CL. Sleep disorders associated with risk of prostate cancer: a population-based cohort study. *BMC Cancer* 2019;19:146.
- 26 Lee EJ, Suh JD, Cho JH. The incidence of prostate cancer is increased in patients with obstructive sleep apnea: results from the National insurance claim data 2007-2014. *Medicine (Baltimore)* 2021;100:e24659.
- 27 Choi JH, Lee JY, Han KD, et al. Association between obstructive sleep apnoea and breast cancer: the Korean National health insurance service data 2007-2014. Sci Rep 2019;9:19044.
- 28 Madut A, Fuchsova V, Man H, et al. Increased prevalence of obstructive sleep apnea in women diagnosed with endometrial or breast cancer. PLoS One 2021;16:e0249099.
- 29 Bhaskara VK, Mohanam I, Rao JS, et al. Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells. *PLoS One* 2012;7:e30905.
- 30 Li L, Ren F, Qi C, et al. Intermittent hypoxia promotes melanoma lung metastasis via oxidative stress and inflammation responses in a mouse model of obstructive sleep apnea. *Respir Res* 2018;19:28.
- 31 Hemmingsson E, Ekblom Ö, Kallings LV, et al. Prevalence and time trends of overweight, obesity and severe obesity in 447,925 swedish adults, 1995-2017. Scand J Public Health 2021;49:377–83.
- 32 Tishler PV, Larkin EK, Schluchter MD, *et al.* Incidence of sleepdisordered breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing. *JAMA* 2003;289:2230–7.
- 33 Park J, Morley TS, Kim M, et al. Obesity and cancer--mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol 2014;10:455–65.
- 34 The National Board of Health and Welfare. Statistics on cancer incidence 2020: socialstyrelsen. 2021. Available: https://www. socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/ statistik/2021-12-7701.pdf
- 35 Kheirandish-Gozal L, Gozal D. Obstructive sleep apnea and inflammation: proof of concept based on two illustrative cytokines. *Int J Mol Sci* 2019;20:459.
- 36 Unnikrishnan D, Jun J, Polotsky V. Inflammation in sleep apnea: an update. *Rev Endocr Metab Disord* 2015;16:25–34.
- 37 Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. *Front Immunol* 2011;2:98.
- 38 Ekström M, Albrecht D, Andersson S, et al. Validation of the swedevox registry of continuous positive airway pressure, long-term mechanical ventilator and long-term oxygen therapy. ERJ Open Res 2021;7:00340-2020.
- 39 Lea G. National guidlines for for treatment of sleep apnea in adults. 2021. Available: https://sesar.registercentrum.se/riktlinjer/nationelltvardprogram-foer-behandling-av-soemnapne-hos-vuxna/p/ HkusG6OcK [Accessed 30 Apr 2022].
- 40 Tan BKJ, Teo YH, Tan NKW, et al. Association of obstructive sleep apnea and nocturnal hypoxemia with all-cancer incidence and mortality: a systematic review and meta-analysis. J Clin Sleep Med 2022;18:1427–40.
- 41 Axelsson Fisk S, Lindström M, Perez-Vicente R, *et al.* Understanding the complexity of socioeconomic disparities in smoking prevalence in Sweden: a cross-sectional study applying intersectionality theory. *BMJ Open* 2021;11:e042323.